BAGSVAERD, Denmark – Novo Nordisk plans to make its NovoPen 6 and NovoPen Echo available in key markets in early 2019. The company has also announced partnership agreements with Dexcom, Glooko and Roche to integrate its connected insulin pen technology into their digital health solutions. “Our non-exclusive partnership strategy allows us to integrate with the various digital platforms that people are already using to help manage their diabetes,” said Camilla Sylvest, executive vice president of commercial strategy and corporate affairs at Novo Nordisk, in a statement. “We firmly believe that this will help more people realize the full benefit of our innovative medicines and begin to ease the mental burden of diabetes treatment for those individuals.” Building on its existing work with IBM Watson Health and Glooko, Novo Nordisk aims to integrate insulin-dosing data from connected pen devices with open ecosystems and diabetes management solutions, such as data from continuous glucose monitoring systems and blood glucose meters. Beyond launching connected durable devices, Novo Nordisk also expects to deliver connectivity for its disposable, pre-filled injection pens later in 2019, said Sylvest.
You are here: / / Novo Nordisk plans to launch connected insulin pens early next year